Predicting Risk of Heroin Overdose, Remission, Use, and Mortality Using Ensemble Learning Methods in a Cohort of People with Heroin Dependence
-
Published:2024-02-26
Issue:
Volume:
Page:
-
ISSN:1557-1874
-
Container-title:International Journal of Mental Health and Addiction
-
language:en
-
Short-container-title:Int J Ment Health Addiction
Author:
Marel ChristinaORCID, Afzali Mohammad H., Sunderland Matthew, Teesson Maree, Mills Katherine L.
Abstract
AbstractDespite decades of research demonstrating the effectiveness of treatments for heroin dependence, rates of heroin use, dependence, and death have dramatically increased over the past decade. While evidence has highlighted a range of risk and protective factors for relapse, remission, and other outcomes, this presents clinicians with the challenge as to how to synthesise and integrate the evolving evidence-base to guide clinical decision-making and facilitate the provision of personalised healthcare. Using data from the 11-year follow-up of the Australian Treatment Outcome Study (ATOS), we aimed to develop a clinical risk prediction model to assist clinicians calculate the risk of a range of heroin-related outcomes at varying follow-up intervals for their clients based on known risk factors. Between 2001 and 2002, 615 people with heroin dependence were recruited as part of a prospective longitudinal cohort study. An ensemble machine learning approach was applied to predict risk of heroin use, remission, overdose, and mortality at 1-, 5-, and 10 + year post-study entry. Variables most consistently ranked in the top 10 in terms of their level of importance across outcomes included age; age first got high, used heroin, or injected; sexual trauma; years of school completed; prison history; severe mental health disability; past month criminal involvement; and past month benzodiazepine use. This study provides clinically relevant information on key risk factors associated with heroin use, remission, non-fatal overdose, and mortality among people with heroin dependence, to help guide clinical decision-making in the selection and tailoring of interventions to ensure that the ‘right treatment’ is delivered to the ‘right person’ at the ‘right time’.
Funder
Australian National Health and Medical Research Council University of Sydney
Publisher
Springer Science and Business Media LLC
Reference83 articles.
1. Adler, E. D., Voors, A. A., Klein, L., Macheret, F., Braun, O. O., Urey, M. A., Zhu, W., Sama, I., Tadel, M., Campagnari, C., Greenberg, B., & Yagil, A. (2020). Improving risk prediction in heart failure using machine learning. European Journal of Heart Failure, 22(1), 139–147. 2. Australian Institute of Health and Welfare (2021a) Alcohol and other drug treatment services in Australia annual report, AIHW, Australian Government. Accessed 18 Feb 2023 3. Australian Institute of Health and Welfare (2021b) Alcohol, tobacco & other drugs in Australia, AIHW, Australian Government. Accessed 20 Feb 2023 4. Bates, S. (2010). Progress towards personalized medicine. Drug Discovery Today, 15(3–4), 115–120. https://doi.org/10.1016/j.drudis.2009.11.001 5. Calderwood, L., & Lessof, C. (2009). Enhancing longitudinal surveys by linking to administrative data. In P. Lynn (Ed.), Methodology of Longitudinal Surveys (pp. 55–71). John Wiley & Sons.
|
|